BioCentury | Mar 31, 2021

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

Achilles Therapeutics Inc. (NASDAQ:ACHL) briefly traded above its $18 IPO price before ceding ground in its first day of trading, settling to $16.55 in trading Wednesday. The clinical T cell therapeutics developer raised $175.5 million through...
BioCentury | Mar 25, 2021

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

Twist Bioscience Corp. (NASDAQ:TWST) said it and partner Biotia Inc. received emergency use authorization from FDA for the first hybridization capture-based next-generation sequencing SARS-CoV-2 assay. The SARS-CoV-2 NGS Assay can sequence and surveil the evolution of virus...
BioCentury | Mar 24, 2021
Product Development

Akero to advance NASH therapy in patients with compensated cirrhosis following Phase IIa readout

While Akero’s NASH therapy did not lead to the same levels of efficacy in patients with compensated cirrhosis as it did in less severe patients, the company views the data as sufficient to move into...
BioCentury | Mar 4, 2021

Precision oncology readout becomes Five Prime’s denouement, driving $1.9B Amgen takeout

Roughly 19 years into Five Prime’s tortuous history, a target-validating readout in a genetically-defined subset of cancer patients spurred the biotech’s $1.9 billion buyout by Amgen, representing the latest signal of outsized interest in precision...
BioCentury | Feb 6, 2021
Product Development

Incyte continues layering on new opportunities

The next stage of Incyte’s growth strategy is already well under way as the company continues to expand its cancer portfolio and prepares to bring its first dermatology program to market.  Much of the current...
BioCentury | Jan 30, 2021

Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

Among the therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm that have convenient routes of administration.  The agency backed Kesimpta ofatumumab, an auto-injectable anti-CD20 mAb from Novartis AG (NYSE:NVS; SIX:NOVN),...
BioCentury | Jan 9, 2021

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Dec 4, 2020

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

Two years after its launch, precision oncology company Kinnate has become at least the twenty-second preclinical biotech to go public on NASDAQ this year, building upon a record the 2020 IPO class broke...
BioCentury | Nov 20, 2020

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
BioCentury | Nov 14, 2020

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
Items per page:
1 - 10 of 909